ホーム › 子宮内膜がん › オハイオ › Columbus
Columbus、OHにおける子宮内膜がんの臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- 他13件
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
被験者募集中第1相
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 他8件
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
被験者募集中第2相
- Ohio State University Comprehensive, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Columbus
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
被験者募集中第3相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
被験者募集中第3相
- Ohio State University, Hilliard · 10マイル先
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- The Ohio State University (OSU) Wexner Medical Center, Columbus
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
被験者募集中第3相
- Research Site, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- The Ohio State University, Columbus
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
被験者募集中第1/2相
- Research Site, Columbus
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
被験者募集中第2相
- Ohio State University, Hilliard · 10マイル先
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
被験者募集中第1相
- Ohio State University Wexner Medical Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Columbus
- Research Site, Hilliard · 10マイル先
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Stefanie Spielman Comprehensive Breast Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Stefanie Spielman Comprehensive Breast Center, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Columbus
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
被験者募集中第2/3相
- OhioHealth Institute, Columbus
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- Philadelphia, PA28件の研究
- San Antonio, TX27件の研究
- Chicago, IL25件の研究
- Queens, NY25件の研究
- Oklahoma City, OK25件の研究
Columbusにおける他の研究
- 非小細胞肺癌56件の研究
- 乳がん39件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 大腸癌24件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
- 悪性黒色腫21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。